Cardiovascular benefits from diabetes drug aren’t for all


More work needs to be done to examine the real world effects of empagliflozin, new research finds Examining data from over 60,000 patients with type 2 diabetes, researchers from the University of Surrey found that the highly-publicised cardiovascular benefits of empagliflozin cannot be applied to the majority of patients with the illness. The study, Sodium-Glucose

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Doctors overtake pharmacists in image poll
Next Australia shines on viral hepatitis policy